

Date:12-11-2023

To Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001

Dear Sir/Madam,

<u>BSE Scrip: PHARMAID | Code: 524572 ISIN: INE117D01018|</u> <u>Sub: Disclosure of Related Party Transactions for the half year ended September 30, 2023</u> <u>Ref: Compliance under Regulation 23 (9) of SEBI (Listing Obligations and Disclosure</u> <u>Requirements) Regulations, 2015.</u>

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith disclosure on Related Party Transactions of the Company for the half year ended September 30, 2023.

Submitted for your kind information and record.

Thanking you,

Yours faithfully,

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar (Company Secretary & Compliance Officer)



Pharmaids Pharmaceuticals Limited- Disclosure of Related Party Transactions for the half year ended 30th September, 2023

S.	Details of the	Details	of the	Type of	Value of	Value of	In case m	ionies are	Addition	al disclos	ure of relat	ted party trans	actions - ap	plicable on	ly in case the	e related	
N	party (listed	counterpa	rty	related party	the	transaction	due to		party tra	nsaction	relates to le	oans, inter-corporate deposits,					
0	entity	-		transaction	related during the eith			arty as a	advances or investments made or given by the listed entity/subsidiary. These d								
	/subsidiary)			(See Note 5)	reporting						ce, during the reporting period when such transaction was						
	entering into the				transact	period	transacti	on		undertaken.							
	transaction				ion as	(See Note			In case	e anv	financial	Details of the	e loans, inte	er-corporat	e deposits, a	dvances	
					approve	6b)					curred to	or investmen	,	F			
					d by the			make or give									
					audit				loans, inter-corporate								
					committ				deposits, advances or								
					ee				investme		1005 01						
	Name	Name	Relationshi		(See		Openin	Closing	Nature	Cost	Tenure	Nature	Interest	Tenure	Secured/	Purpo	
	ivanic	Ttanic	p of the		Note			balance	of	(See	Tenure	(loan/	Rate	Tenure	unsecure	se for	
			counterpar		6a)		g balance	Dalance	indebte	Note		advance/	(%)		d	which	
			ty with the		04)		Dalance		dness			intercorpo	(70)		u	the	
			v							7)		-				funds	
			listed entity						(loan/			rate				will	
			or its						issuanc			deposit/					
			subsidiary						e of			investment				be	
									debt/							utilise	
									any							d by	
									other							the	
									etc.)							ultim	
																ate	

PHARMAIDS PHARMACEUTICALS LIMITED (CIN: L52520KA1989PLC173979) Registered Office.: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013 INDIA Phone: 080-49784319 Email: compliance@pharmaids.com WEB: www.pharmaids.com



																recipi ent of funds (end- usage)
1.	Pharmaids Pharmaceuticals Limited	Venu Madhava Kaparthy – Executive Director	Key Manageme nt Personnel	Remuneration	-	18,00,000/-	-	-	_	-	-	-	-	-	_	-
2.	Pharmaids Pharmaceuticals Limited	Mini Manikant an – Executive Director	Key Manageme nt Personnel	Remuneration	-	12,00,000/-	-	-	-	-	-	-	-	-	-	-
3.	Pharmaids Pharmaceuticals Limited	Balagang adhara B C - Chief Financial Officer	Key Manageme nt Personnel	Remuneration	-	13,50,000/-	-	-	-	-	-	-	-	-	-	-
4.	Pharmaids Pharmaceuticals Limited	Kaushik Kumar – Company Secretary	Key Manageme nt Personnel	Remuneration	-	6,00,000/-	-	-	-	-	-	-	-	-	-	-

PHARMAIDS PHARMACEUTICALS LIMITED (CIN: L52520KA1989PLC173979) Registered Office.: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013 INDIA Phone: 080-49784319 Email: compliance@pharmaids.com WEB: www.pharmaids.com



5.	Pharmaids	Anugraha	Associate	-	- 85,00,000	-	-	-	-	-	-	-	-	-
	Pharmaceuticals	Chemical	(as per IND											
	Limited	s	AS)											

Notes:

- 1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
- 2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
- 3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
- 4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six-month period shall apply accordingly.
- 5. Each type of related party transaction (for e.g., sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
- 6. In case of a multi-year related party transaction:
 - a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".

b. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".

- 7. "Cost" refers to the cost of borrowed funds for the listed entity.
- 8. PAN will not be displayed on the website of the Stock Exchange(s).

PHARMAIDS PHARMACEUTICALS LIMITED (CIN: L52520KA1989PLC173979



9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar

(Company Secretary & Head-Legal)

PHARMAIDS PHARMACEUTICALS LIMITED (CIN: L52520KA1989PLC173979)